Abatacept - Rheumatoid arthritis
You are here : Home > Formulary Search > Abatacept - Rheumatoid arthritis
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
Red
Formulations :
- Intravenous infusion
- Subcutaneous injection (sc)
Formulary Status :
Associated Icons :
Restrictions / Comments :
Documentation
NICE Technology Appraisal
NICE Technology Appraisal
NICE Technology Appraisal
PAD Profile
ChemicalSubstance :
Abatacept
Indication :
Rheumatoid arthritis
Group Name :
Keywords :
RA, Biologic, NICE, immunosuppressant, T-cell co-stimulation inhibitor, DMARD, Bdmard, Disease modulating, Rheumatology
Brand Names Include :
Orencia
Important Information :
Severe disease only. NON-FORMULARY for moderate disease
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
4
Committee Recommendations (1)
Abatacept is NON-FORMULARY for moderate disease.
The Surrey Heartlands integrated care system Area Prescribing Committee (APC) agrees with the recommendations made in NICE TA715.
Abatacept for moderately active Rheumatoid Arthritis was not recommended by NICE and will be given a NON-FORMULARY traffic light status for this indication. The current treatment pathway is attached below.
Other Indications
Below are listed other indications that Abatacept is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Rheumatoid arthritis.